血管胺酶抑制剂 血管胺酶抑制剂
1Office of Scientific Affairs, SUNY Downstate Medical College, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 97, Brooklyn, NY 11203, USA. mweber@downstate.edu
Lancet (London, England)
|November 14, 2001
概括
新的血管酶抑制剂具有双重作用,降低血压并改善高血压和心力衰竭模型中的心血管健康. 临床试验表明,在不同的人群中有效,可能超过目前的治疗方法.
科学领域:
- 心血管药理学心血管药理学
- 药物发现 药物发现 药物发现
- 高血压研究 高血压研究
背景情况:
- 血管酶抑制剂代表了一种新的心血管药物类别.
- 它们同时抑制中性内皮酶和血管素转化酶 (ACE).
- 这种双重抑制调节了血管扩张性和血管酶II的产生.
研究的目的:
- 评估血管酶抑制剂的疗效和安全性.
- 评估它们在治疗高血压,心力衰竭和缺血性心脏病方面的潜力.
- 为了比较它们与现有的抗高血压药物的有效性.
主要方法:
- 对高血压,心力衰竭和缺血性心脏病的临床前动物模型的审查.
- 对人类高血压和充血性心力衰竭的临床研究的分析.
- 检查安全性概况和副作用的频率,包括血管和咳.
主要成果:
- 在动物模型中,血管酶抑制剂降低了各种高血压类型的血压,并在心力衰竭和缺血性心脏病中显示出好处.
- 人类研究表明,不论种族或年龄,有效降低血压.
- 主要药物奥马帕特里拉 (Omapatrilat) 显示出比目前的ACE抑制剂和其他抗高血压药物更高的疗效,对心力衰竭有积极影响.
结论:
- 血管酶抑制剂显示出作为高血压和心力衰竭的有效治疗方法的希望.
- 它们的安全性似乎与ACE抑制剂相当,尽管需要更多关于副作用的数据.
- 大规模的临床终点试验至关重要,以确定它们与既有疗法一起发挥的作用.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...


